Debiopharm & EORTC investigate triptorelin for treatment of salivary gland cancers

(European Organisation for Research and Treatment of Cancer) Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, today announced a collaboration in order to supply triptorelin pamoate 3.75 mg one-month formulation for patients suffering from salivary gland cancer participating in a clinical study sponsored by the European Organisation for Research and Treatment of Cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news